Mentions
Extended reach
Total likes
Video views
AI synopsis
The digital discussions reflect an overall interest in how patients and researchers weigh the urgency of access against the certainty of benefit, with phrases like 'challenging accelerated approval' and 'many prefer waiting' showing active engagement with the article's implications. The tone varies from analytical to cautiously optimistic, emphasizing the study's relevance to current debates on drug approval standards.
Most discussions recognize the importance of balancing access speed and survival benefits, suggesting a moderate support for the publication's focus.
Posts show strong curiosity, with many references to the relevance of the research, indicating high interest in the topic of cancer drug approval processes.
Several posts highlight key points from the study, such as the willingness of patients to wait for more certain benefits, demonstrating a thoughtful level of engagement.
The discussions imply that the findings could influence future policy or clinical decisions regarding cancer drug approvals, indicating perceived moderate impact.
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment This study explored how willing cancer patients and their acquaintances are to accept uncertainty about the benefits of new cancer drugs in exchange for https://t.co/vfrHM1oHAM
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs @TheLancetOncol https://t.co/jYzkSsCImA
Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discrete choice experiment https://t.co/saTfZIL4px
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - The Lancet Oncology https://t.co/xtfuU9hJS5
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs Findings suggest many prefer waiting for more evidence of survival benefits, challenging the accelerated approval pathway for cancer drugs lacking clear survival advantages. https://buff.ly/3ZbZyU2
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment https://t.co/BjFMP1MgBg via @AggarwalOnc et al https://t.co/S60WoN4C19
This panel critically examines recent FDA approval processes for oncology and Alzheimer's treatments, highlighting controversies surrounding accelerated approvals, surrogate endpoints, and safety concerns, and…
Weighing the pros and cons of the accelerated approval pathway as it relates to oncology. The video discusses an updated FDA draft guidance and public perceptions of newly approved cancer drugs, highlighting the balance…
RT @consiliumsci:
RT @consiliumsci:
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - The Lancet Oncology https://t.co/TOeB1GAnSW
RT @ArndtVogel: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs @TheLancetOncol https://t.co/…
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs @TheLancetOncol doi.org/10.1016/S147...
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs @TheLancetOncol https://t.co/jYzkSsCImA
RT @TheLancetOncol: Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discret…
[Articles] Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment #science #publication #research #journal https://t.co/VstgWbVHpT
RT @NaultJc: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - T…
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - The Lancet Oncology https://t.co/lTf9CfCNjB
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
RT @TheLancetOncol: Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discret…
RT @TheLancetOncol: Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discret…
RT @TheLancetOncol: Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discret…
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
RT @NaultJc: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - T…
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
RT @TheLancetOncol: Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discret…
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
RT @OncoAlert: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment…
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - The Lancet Oncology https://t.co/xtfuU9hJS5
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment This study explored how willing cancer patients and their acquaintances are to accept uncertainty about the benefits of new cancer drugs in exchange for https://t.co/vfrHM1oHAM
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs Findings suggest many prefer waiting for more evidence of survival benefits, challenging the accelerated approval pathway for cancer drugs lacking clear survival advantages. https://buff.ly/3ZbZyU2
RT @TheLancetOncol: Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discret…
Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discrete choice experiment https://t.co/saTfZIL4px
RT @pash22: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment http…
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment https://t.co/BjFMP1MgBg via @AggarwalOnc et al https://t.co/S60WoN4C19